Molecular Role of EGFR-MAPK Pathway in Patchouli Alcohol-Induced Apoptosis and Cell Cycle Arrest on A549 Cells In Vitro and In Vivo

XinGang Lu, 1 Liu Yang, 2 ChengHua Lu, 3 ZhenYu Xu, 4 HongFu Qiu, 1 JiaJia Wu, 5 JingWen Wang, 6 JiaFeng Tong, 1 Yin Zhu, 1 and Jie Shen 7

1 Department of Traditional Chinese Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China
2 Department of Oncology, Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201999, China
3 Department of Respiratory, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China
4 Department of Traditional Chinese Medicine, Wujing Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200241, China
5 Department of Rehabilitation, The Second People Huaian Hospital, Xuzhou Medical College, Huaian 223002, China
6 Department of Oncology, Huadong Hospital, Fudan University, Shanghai 200040, China
7 Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai 200040, China

Correspondence should be addressed to Jie Shen; shj421@126.com

Received 5 May 2016; Accepted 20 July 2016

Academic Editor: Pratheeshkumar Poyil

Copyright © 2016 XinGang Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nowadays, chemotherapy is still the main effective treatment for cancer. Herb prescriptions containing Pogostemon cablin Benth (also known as Guang-Huo-Xiang) have been widely used in Chinese medicine today. In our research, we found that patchouli alcohol, a compound isolated from the oil of Pogostemon cablin Benth, exerted antitumor ability against human lung cancer A549 cells both in vitro and in vivo. MTT assay was used to assess cell viability. Hoechst 33342 staining and TUNEL cover glass staining provided the visual evidence of apoptosis. Caspase activity measurement showed that patchouli alcohol activated caspase 9 and caspase 3 of mitochondria-mediated apoptosis. Consistently, patchouli alcohol inhibited the xenograft tumor in vivo. Further investigation of the underlying molecular mechanism showed that MAPK and EGFR pathway might contribute to the antitumor effect of patchouli alcohol. Our study proved that patchouli alcohol might be able to serve as a novel antitumor compound in the clinical treatment of lung cancer.

1. Introduction

Pogostemon cablin Benth, also known as Guang-Huo-Xiang in China, is a medicinal plant widely planted in Philippines, Malaysia, India, and China [1]. In the clinical practice of traditionally Chinese medicine, Guang-Huo-Xiang has been widely used in numerous prescriptions including Lianhua-Qingwen capsule [2]. Additionally, the patchouli oil, a nature perfume from Guang-Huo-Xiang, has been widely used to resolve damp, improve appetite, arrest vomiting, and dispel summer-heat as well as summer-damp [3–5] for a long time in history since ancient times in China.

It has been found that patchouli alcohol (PA) is the main effective component of Guang-Huo-Xiang, which accounts for 20–26% weight of the patchouli oil [6]. The chemical structure of PA is shown in Figure 1(a). PA is used for the quality control objective of patchouli oil in pharmaceutical industry (The Pharmacopoeia Commission of PRC 2010). Accumulating reports have demonstrated that PA had multiple effects such as anti-inflammatory [7, 8], antivirus [9–12], antimicrobial [13–17], and insecticidal [18, 19], protective effect on fluidity of intestinal epithelial cells [20], protective effect on acute lung injury [21], radical-scavenging activity.
Figure 1: Continued.
[22], inhibitory activity on platelet-activating factor (PAF) activation [23], and antiemetic activity [24].

Recently, several studies have revealed the anticancer activity of PA and the possible underlying mechanisms. PA suppressed cell proliferation and induced apoptosis in a concentration-dependent manner in two human colorectal cancer cell lines (HCT116, SW480). Moreover, PA suppressed cell growth in MCF7, BxPC3, PC3, and HUVEC cells. PA treatment to HCT116 and SW480 cells triggered p21 expression and inhibited the expressions of Cyclin D1 and Cyclin-dependent kinase 4 (CDK4). Meanwhile, PA attenuated the expressions of histone deacetylases (HDACs) and c-myc, in two human colorectal cancer cells. PA treatment also resulted in the transcriptional activity of NF-κB via an increase of p65 nuclear translocation [25]. Additionally, PA inhibited the proliferation of HeLa cells in vitro [26].

However, the anticancer ability on human lung cancer of PA has not been investigated. In this study, we found that PA was able to suppress the growth of A549 cells both in vitro and in vivo. Treatment of PA induced apoptosis in and arrested the cell cycle progression of A549 cells. Further investigation on the molecular mechanism showed that PA inhibited the phosphorylation of EGFR and thereby blocked the downstream signaling, which may be responsible for the anticancer activity of PA. Our study proved that PA might serve as a potential compound for the treatment of non-small-cell lung cancer in the clinical practice and provided more insights for developing novel anticancer agents from medicinal plants.

2. Materials and Methods

2.1. Materials. Pancreatin, penicillin, RPMI-1640 medium, Fetal Bovine Serum (FBS), Phosphate Buffered Saline (PBS), and streptomycin were supplied from Gibco (Gibco, Carlsbad, USA); A549, L02, HEK293, and HFL-1 cells were gained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). Terminal Deoxynucleotidyl Transferase (TdT)- mediated dUTP nick end labeling (TUNEL) Apo-Green Detection Kit was supplied by Roche (Roche, Basel, Switzerland), while Annexin V&PI Kit was purchased by Biotool (Selleck Chemicals, Houston, Texas, USA). Protein extraction kit, RNA extraction kit, BCA Protein Assay Kit, caspases 3 and 9 activity kit, Propidium Iodide (PI), dimethylsulfoxide (DMSO), 4′,6-diamidino-2-phenylindole (DAPI), and Hoechst 33243 were purchased from Beyotime Institute of Biotechnology (Beyotime, Haimen, China). PA standard preparation (purity > 98%) was purchased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). JC-10 Mitochondrial Membrane Potential Assay Kit was obtained by AAT Bioquest (AAT Bioquest, CA, USA). ECL Advanced Detection Kit was provided by Thermo Fisher (Thermo Fisher, Waltham, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and albumin from bovine serum (ABS) were purchased from Sigma-Aldrich (St. Louis, USA). Desired primary antibodies, HRP-labeled secondary anti-mouse/anti-rabbit antibodies, were provided by Cell Signaling Technology (CST, Beverly, USA). All other unmentioned chemical reagents were of analytic grade.
2.2. Cell Culture and PA Treatment. A549 carcinoma cell lines and three types of normal cell lines (HEK293, L02, and HFL-1) were cultured in a humidified atmosphere of 5% CO₂ with RPMI-1640 medium containing 10% fetal calf serum and antibiotics (100 IU/mL penicillin and 100 IU/mL streptomycin); PA standard was dissolved in DMSO for further experiment. A549 cells were treated with increasing concentrations of PA for desired hours in PA exposure groups. The control group was conducted with the same volumes of DMSO under the same conditions.

2.3. Cytotoxicity and Cell Viability Analysis. Cytotoxicity of PA on carcinoma and normal cells was analyzed using the MTT assay. The A549, HEK293, L02, and HFL-1 cells were seeded in culture plates and exposed to PA by increasing concentrations. Concisely, 5 × 10⁵ cells were cultured with 200 μL culture medium and 20 μL MTT (5 mg/mL) for 4 hours. The absorbance at 570 nm was assessed using a microplate reader (Perkin-Elmer Inc., Waltham, USA) after removing the supernatant and dissolving the formazan in DMSO. Cell viability of PA-treated cells and control cells was estimated as (absorbance of PA-treated group/absorbance of control) × 100%.

2.4. Hoechst 33342 Staining. The NSCLC A549 cells were cultured and treated with PA as described above. The NSCLC A549 cells were stained with Hoechst 33342 (5 μg/mL) at room temperature for 5 minutes in the dark. Stained cells were observed by an inverted immunofluorescence microscopy (D5100, Nikon, Tokyo, Japan).

2.5. TUNEL Staining. DNA fragmentation in apoptotic cells induced by anticarcinoma drugs can be detected by TUNEL staining assay according to the manufacturer’s instruction. The NSCLC A549 cells after PA treatment and control were fixed by TUNEL and DAPI. We analyzed the PA-treated group and control cells immediately using immunofluorescence microscopy described above to view the green (TUNEL) at 520 nm and the blue (DAPI) at 460 nm.

2.6. Flow Cytometry for Cell Cycle and Apoptosis Measurement. To detect the cell cycle and apoptotic subpopulation in PA-treated A549 cells, the A549 cells were cultured and induced by PA as mentioned. PA-treated A549 cells were harvested, stained with Annexin-FITC/PI, and measured using a FACS Calibur cytometer (BD, Biosciences, San Jose, CA, USA) according to the manufacturer’s instruction. As for the investigation of cell cycle progression, PA-treated cells were harvested, fixed, and stained with PI according to the manufacturer’s instruction and then measured by the FACS Calibur cytometer.

2.7. Mitochondrial Membrane Potential (MMP). AAT JC-10 assay kit was used to measure the loss in mitochondrial membrane potential of PA-treated A549 cells. PA-treated A549 cells were stained according to the manual and then the fluorescence was measured using a microplate reader (Perkin-Elmer Inc., Waltham, USA). The MMP was indicated by the ratio of the green fluorescence absorbance at 525 nm to the red fluorescence absorbance at 590 nm.

2.8. Caspases 3 and 9 Activity Assay. Caspases 3 and 9 activities were determined by using caspases 3 and 9 activity kit according to the kit instruction manual. Release of p-nitroanilide (pNA) was determined by absorbance at 405 nm using a microplate reader (Perkin-Elmer Inc., Waltham, USA). The caspase activity was demonstrated as the ratio of PA-treated cells/control A549 cells.

2.9. In Vivo Study. We conducted all the animal experiments according to the Declaration of Helsinki and the Guide for the Care and the Use of Laboratory Animals as adopted and promulgated by the United States National Institutes of Health. The animal study was licensed by the Institutional Animal Care and Use Committee of Fudan University. The 6-week-old BALB/C nude mice (Shanghai Slac Laboratory Animal) were injected with A549 cells intraperitoneally with 1 × 10⁶ cells per mouse. There were 4 randomly divided groups (6 mice each group): control group (vehicle) and PA treatment group with low, medium, and high PA dose. PA standard crystal was dissolved in saline containing 5% DMSO. When the volume of the tumor reached 100 mm³, 200 μL 5% DMSO/saline solutions including increasing dose of PA were injected intraperitoneally into the right flank of nude mice in PA treatment group. The disinfesting saline in same volumes containing 5% DMSO was administrated into the vehicle group. PA was injected into all the PA treatment groups every 3 days. After the last treatment, the nude mice were put to death in 24 h. Tumor xenografts removed from mice were measured and fixed for next experiment. Tumor sizes were evaluated every 3 days using micrometer calipers, and tumor weights were determined at last.

2.10. Immunohistochemistry. The A549 xenografted tumor samples were stained using cleaved-caspase 3 (1:100) and Ki67 (1:150) antibodies separately for immunohistochemistry. Images were recorded with a fluorescence microscope (D5100, Nikon, Tokyo, Japan).

2.11. Western Blotting. The levels of apoptotic proteins were analyzed by western blotting analysis. Proteins of PA-treated cells and control were extracted by the extraction kit; protein concentrations were measured using BCA protein assay kit. The proteins were subjected to SDS-PAGE and electrophoretically transferred to PVDF membrane (Millipore Corp, Bedford, MA, USA). The membranes were incubated with desired primary antibodies (1:1000) and incubated with secondary antibody (1:5000) conjugated with peroxidase subsequently. These signals were then detected by a detection system (BD Biosciences, San Jose, CA, USA). The β-actin antibody was employed as control.

2.12. Statistical Analysis. Triplicate experiments were conducted with independent samples. The data were represented as mean ± SD. Statistical intergroup differences were evaluated using one-way ANOVA followed by post hoc Bonferroni
3. Results

3.1. Effect of PA Antigrowth Capability in Four Cells. We first investigated whether PA treatment could inhibit the growth of non-small-cell lung cancer cells. The A549 is most common cell model used for multiple anti-lung cancer research [27]. In our results, it was shown that PA suppressed the growth of A549 cells in a concentration-and time-dependent manner (Figure 1(b)). Lower viability was observed in A549 cells treated with PA for 48 h. The IC50 value of PA on A549 cells was 79.80 ± 4.09 μg/mL. Further, we determined the cytotoxicity of PA in human normal cells: L02, HEK293, and HFL-1. However, more than 60% of cells were still viable when treated with PA of the concentration up to 300 μg/mL (Figure 1(c)). Taken together, these data suggested that PA might serve as a potent and safe anticancer agent against non-small-cell lung cancer.

3.2. Effects of PA on Cell Apoptosis In Vitro. The best performances based on MTT results indicate that 48 h was best experiment time. PA exposure at 50–100 μg/mL at 48 h treated cells showed a marked increase by Annexin V/PI assay shown in Figure 1(d). The apoptotic population in PA-treated A549 cells increased in a dose-dependent manner. We further hypothesized that PA might induce apoptosis via the mitochondrial pathway. Firstly, western blotting assays showed prompted cleavage of PARP and caspases 3 and 9 in PA-treated cells. Additionally, PA inhibited the expression of Bcl-2 but had little effect on the level of Bax, which led to decreased ratio of Bcl-2/Bax (Figure 1(e)). Consistent with above result, JC-10 assays determine the PA's impact on the expression of P53, P21, and 9 in PA-treated cells. Additionally, PA inhibited the apoptosis elicited by PA exposure was observed visually as well. Hoechst staining exhibited image results with shrinkage, nuclear fragmentation, and chromatin compaction of PA-treated cells, indicating apoptosis induction as well (Figure 2(d)). Consistently, TUNEL staining demonstrated that PA at the concentration of 50–100 μg/mL led to significantly increased population of apoptotic cells (green, Figure 2(e)).

Western blotting of the PA treatment A549 versus control showed the apoptosis-related signal pathway. In present survey, we found that the phosphorylation of EGFR, a critical tyrosine kinase in the genesis and development of numerous human cancers, was suppressed by PA treatment. The phosphorylation level of EGFR pathway activities (JNK, ERK, and P38) were also evaluated after PA treatment. As shown in Figure 2(f), western blotting indicated that phosphorylation of ERK (which lies downstream of EGFR) was downregulated. However, PA caused the increasing of p-JNK while showing no impact on p-P38. The phosphorylation activation of JNK signaling pathway and downphosphorylation of EGFR pathway induced the MMP loss. These caused the unbalance of Bcl-2/Bax which elicits the following mitochondrial apoptosis pathways: releasing of c-Myc and activation of caspase 9 and caspase 3 subsequently.

3.3. Effects of PA on the Cell Cycle Arrest In Vitro. We conducted cell cycle assay to evaluate the PA’s impact on A549 using PI. Meanwhile, we performed western blotting to reveal the underlying mechanism. Figure 3(a) manifested an accumulating cell cycle progression in G1/S phase in a dose-dependent manner in PA-treated A549 cells. Then, we determined the PAs impact on the expression of P53, P21, Cyclin E, and Cyclin-dependent kinase 2 (CDK2). Western blotting demonstrated that the expression level of P53 was activated in a dose-dependent manner and an appreciable downregulation of Cyclin E and CDK2 subsequently (Figure 3(b)).

3.4. Antiproliferation Effect of PA on A549 Nude Xenograft Tumor. We performed a study in vivo to investigate the antiproliferation effect of PA on A549 nude xenograft tumor. There were few changes in mice body weight in the experiment, as shown in Figure 4(a). This implied the relative safety of the injection of PA to the nude mice. After 21 days, tumors treated with PA grew smaller than control, as shown in Table 1.

### Table 1: The inhibitory effect of PA on A549 implantation tumor growth in BALB/C-nu mice.

| Groups (mg/kg) | Number of animals survived | Body weights (g) Start | End | Tumor weights (g) | Inhibition rate (%) |
|---------------|---------------------------|------------------------|-----|------------------|-------------------|
| Control       | 6                         | 20.38 ± 0.66           | 24.78 ± 0.93 | 1.35 ± 0.18      |                   |
| 5             | 6                         | 20.7 ± 0.44            | 24.48 ± 0.68 | 0.78 ± 0.11*     | 42.35             |
| 10            | 6                         | 20.67 ± 0.42           | 24.48 ± 1.43 | 0.51 ± 0.23***   | 62.50             |
| 15            | 6                         | 20.67 ± 0.41           | 23.38 ± 0.57 | 0.27 ± 0.19***   | 79.70             |

*P < 0.05 versus the vehicle control. **P < 0.01 versus the vehicle control. ***P < 0.001 versus the vehicle control.
Figure 2: Continued.
Figure 2: The apoptosis effect and involved signaling pathway activity of PA on A549 cells. The A549 cells were exposed for 48 h with increasing PA. (a) PA induced MMP collapse for 48 h treatment. (b) PA exposure induced caspase 9 activation in A549 cells for 48 h. (c) PA exposure induced caspase 3 activation in A549 cells for 48 h. (d) The Hoechst staining immunofluorescence microscopy image of A549 cells for Hoechst \textit{in vitro}; Scale Bar: 10 \textmu m. (e) The TUNEL staining immunofluorescence microscopy image of A549 cells for DAPI (blue), TUNEL FITC (green), and their merge \textit{in vitro}; Scale Bar: 50 \textmu m. (f) Effect of PA on EGFR and MAPK signaling pathways in A549 cells. Statistical differences were compared between PA treatment group and control group and considered significant at the levels of \(* P < 0.05\), \(* * P < 0.01\), or \(* * * P < 0.001\).

and Figures 4(b) and 4(c). The significantly decreasing levels of Ki67-positive cells and the increasing levels of cleaved-caspase 3 induced by the PA treatment were found in the study \textit{in vivo} as shown in Figure 4(d). The study \textit{in vivo} demonstrated the effects of apoptosis and antiproliferation effect of PA as well.

4. Discussion

\textit{Pogostemon cablin} Benth possessed multiple pharmacology activities in previous reports [5]. PA is the main biological active constituent of \textit{Pogostemon cablin} Benth. Published studies had shown that PA inhibited the proliferation of several carcinoma cells and normal cells such as HUVEC [25]. However, higher IC_{50} in our study demonstrated tissue specific effect of PA on HEK293 (normal kidney cell), L02 (normal liver cell), and HFL-1. Exposure to PA caused apoptosis and cell cycle arrest in A549 in a time- and dose-dependent manner. Therefore, PA may be a candidate anti-tumor agent although the administration or the structure of PA may call for new efforts in future.

Scientists paid attention to the drug’s antiproliferation effect and intrinsic mechanism during the past decades [28–30]. Antiproliferation mechanisms are commonly associated with apoptosis and cell cycle arrest [31]. Firstly, we observed that the antiproliferation is activated by apoptosis through TUNEL and Hoechst staining. Using flow cytometry analysis, the apoptosis induced by PA was validated by Annexin V/PI assay. Apoptosis by caspase activations has two main types: caspase 8 activation is linked to extrinsic apoptotic pathway downstream death receptor like TNF-\alpha receptor while caspase 9 activation is involved in the intrinsic mitochondrial
apoptotic pathways [32]. Anticancer drugs induce caspase 9 activation in most apoptosis cases [33]. As demonstrated by caspase activation assay and western blotting, caspases 9 and 3 activations in PA exposure were detected. The Bcl-2 family proteins play important roles in apoptosis [34]. Two main proteins of Bcl-2 family are the antiapoptotic Bax and the proapoptotic Bcl [35]. The unbalance of Bcl-2/Bax ratio contributes to the loss of MMP [36]. PA caused the unbalance of Bcl-2/Bax, collapse of MMP, and thus cascade of caspase pathway. MMP is an important converge point for many signaling intracellular apoptotic pathways [37]. Transcriptional factor NF-κB plays an important role in the regulation of mitochondrial apoptotic pathway [38]. Many antitumor agents exert their ability through NF-κB signaling pathway.

The antiproliferation effect of PA to A549 cell was weaker than SW480 cell but stronger than HCT116 cell in vitro. However, apparent antitumor effect of PA to A549 xenograft nude model was witnessed in our study in vivo. As previous report mentioned, PA induced two types of human colon cancer cell lines apoptosis via activating NF-κB signaling pathway and downregulating c-myc [25]. Our result is associated with the published reports in mitochondrial apoptotic pathway. Furthermore, we conducted the cell cycle arrest assay in PA-treated A549 cell. In published report, PA treatment in HCT116 and SW480 cells activated P21 expression and suppressed the expressions of Cyclin D1 and Cyclin-dependent kinase 4 (CDK4) in a dose-dependent manner [25]. Similar to previous result, PA induced accumulating G1/S cell cycle.

**Figure 3:** Typical G1/S cell cycle arrest on A549 cells induced by increasing PA exposure of 0, 50, 75, and 100 μg/mL. (a) PA induced G1/S cell cycle arrest. (b) The involved proteins activities. Statistical differences were compared between PA treatment group and control group and considered significant at the levels of * P < 0.05, ** P < 0.01, or *** P < 0.001.
Figure 4: The antiproliferation effect of PA on A549 xenograft model. (a) The body weights of nude A549 models in vivo. (b) The tumor sizes of A549 nude models in vivo. (c) The tumor of each group. (d) Effect of PA on the expression levels of cleaved-caspase 3 and Ki67 in A549 nude model; Scale Bar: 100 μm. Statistical differences were compared between PA treatment group and control group and considered significant at the levels of *P < 0.05, **P < 0.01, or ***P < 0.001.
arrest through activation in P53 and P21 and suppression in CDK2 and Cyclin E.

EGFR plays important roles in cell proliferation, differentiation, oncogenesis, and development [39]. The expression level of EGFR was commonly upregulated in many cancers, for instance, colon [40], ovarian [41], breast [42], and lung especially [43]. We conducted western blotting assay to certify apoptotic mechanism. We used the EGF (100 ng/mL) in activation of EGFR signal pathway [44]. The apoptosis in PA combined with EGF group was decreased compared with PA, while cell cycle distribution was altered, as shown in Figures 1(d) and 3(a). The EGFR phosphorylation levels were reupregulated in the combination group, as shown in Figure 5(a). Our results show that PA treatment significantly blocked the phosphorylation of EGFR and its downstream signaling: phosphorylation of MEK and ERK proteins. Importantly, exotic addition of EGF reactivated the downstream pathway of EGFR and reversed the apoptosis as
well as cell cycle arrest induced by PA. This indicated that blocking the phosphorylation of EGFR is necessary for the cytotoxicity of PA.

In summary, we reported that PA induced apoptosis and cell cycle arrest in A549 cancer cells in vitro and in vivo through blocking phosphorylation of EGFR pathways and activating JNK pathways for the first time to our knowledge. PA also arrests G_{1}/S cycle distribution through impact on CDK2/Cyclin E complex. The graphical mechanism of PA’s action on A549 cells was demonstrated in Figure 5(b). Our findings suggested that PA may be a promising candidate for antitumor agent.

**Competing Interests**

No potential competing interests were disclosed by all authors.

**Authors’ Contributions**

XinGang Lu, Liu Yang, and ChengHua Lu contributed to this work equally.

**Acknowledgments**

This study was financially supported by “Shanghai XinLin New Star Plan” (ZY3-RCPY-2-2081) and State Administration of Traditional Chinese Medicine “Twelfth Five-Year Plan” Key Specialty (Chinese Medicine Geriatrics). Technology supports were obtained from Shanghai Key Laboratory of Clinical Geriatric Medicine.

**References**

[1] J.-B. Liao, Y.-Z. Liang, Y.-L. Chen et al., “Novel patchouli alcohol ternary solid dispersion pellets prepared by poloxamers,” *Iranian Journal of Pharmaceutical Research*, vol. 14, no. 1, pp. 15–26, 2015.

[2] W. Jia, C. Wang, Y. Wang et al., “Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS,” *The Scientific World Journal*, vol. 2015, Article ID 731765, 19 pages, 2015.

[3] L. F. Hu, S. P. Li, H. Cao et al., “GC-MS fingerprint of *Pogostemon cablin* in China,” *Journal of Pharmaceutical and Biomedical Analysis*, vol. 42, no. 2, pp. 200–206, 2006.

[4] M. K. Swamy and U. R. Sinniah, “A comprehensive review on the phytochemical constituents and pharmacological activities of *Pogostemon cablin* Benth.: an aromatic medicinal plant of industrial importance,” *Molecules*, vol. 20, no. 5, pp. 8521–8547, 2015.

[5] S. B. Bhatia, C. S. Letizia, and A. M. Api, “Fragrance material review on patchouli alcohol,” *Food and Chemical Toxicology*, vol. 46, supplement II, pp. S255–S256, 2008.

[6] Z. Zhao, J. Lu, K. Leung, C. L. Chan, and Z.-H. Jiang, “Determination of patchouli alcohol in Herba Pogostemonis by GC-MS-MS,” *Chemical & Pharmaceutical Bulletin*, vol. 53, no. 7, pp. 856–860, 2005.

[7] Y.-F. Xian, Y.-C. Li, S.-P. Ip, Z.-X. Lin, X.-P. Lai, and Z.-R. Su, “Anti-inflammatory effect of patchouli alcohol isolated from *Pogostemonis Herba* in LPS-stimulated RAW264.7 macrophages,” *Experimental and Therapeutic Medicine*, vol. 2, no. 3, pp. 545–550, 2011.

[8] J. B. Jeong, Y. K. Shin, and S.-H. Lee, “Anti-inflammatory activity of patchouli alcohol in RAW264.7 and HT-29 cells,” *Food and Chemical Toxicology*, vol. 55, pp. 229–233, 2013.

[9] H. Kiyohara, C. Ichino, Y. Kawamura, T. Nagai, N. Sato, and H. Yamada, “Patchouli alcohol: in vitro direct anti-influenza virus sesquiterpene in *Pogostemon cablin* Benth.,” *Journal of Natural Medicines*, vol. 66, no. 1, pp. 55–61, 2012.

[10] H. Wu, B. Li, X. Wang, M. Jin, and G. Wang, “Inhibitory effect and possible mechanism of action of patchouli alcohol against influenza A (H2N2) virus,” *Molecules*, vol. 16, no. 8, pp. 6489–6501, 2011.

[11] Y.-C. Li, S.-Z. Peng, H.-M. Chen et al., “Oral administration of patchouli alcohol isolated from *Pogostemonis Herba* augments protection against influenza viral infection in mice,” *International Immunopharmacology*, vol. 12, no. 1, pp. 294–301, 2012.

[12] X.-L. Wu, D.-H. Ju, J. Chen et al., “Immunologic mechanism of patchouli alcohol anti-H1N1 influenza virus may through regulation of the RLH signal pathway in vitro,” *Current Microbiology*, vol. 67, no. 4, pp. 431–436, 2013.

[13] X. Yang, X. Zhang, S.-P. Yang, and X.-D. Yu, “Preliminary antibacterial evaluation of the chemical compositions in Herba pogostemonis oil,” *Pakistan Journal of Pharmaceutical Sciences*, vol. 26, no. 6, pp. 1173–1179, 2013.

[14] X.-D. Yu, J.-H. Xie, Y.-H. Wang et al., “Selective antibacterial activity of patchouli alcohol against Helicobacter pylori based on inhibition of urease,” *Phytotherapy Research*, vol. 29, no. 1, pp. 67–72, 2015.

[15] S. Pattnaik, V. R. Subramanyam, and C. Kole, “Antibacterial and antifungal activity of ten essential oils in vitro,” *Microbios*, vol. 86, no. 349, pp. 237–246, 1996.

[16] X. Yang, X. Zhang, S.-P. Yang, and W.-Q. Liu, “Evaluation of the antibacterial activity of patchouli oil,” *Iranian Journal of Pharmaceutical Research*, vol. 12, no. 3, pp. 307–316, 2013.

[17] D. Vázquez-Sánchez, M. L. Cabo, and J. J. Rodríguez-Herrera, “Antimicrobial activity of essential oils against *Staphylococcus aureus* biofilms,” *Food Science and Technology International*, vol. 21, no. 8, pp. 559–570, 2015.

[18] R. Paveila, “Insecticidal properties of several essential oils on the house fly (*Musca domestica* L.),” *Phytotherapy Research*, vol. 22, no. 2, pp. 274–278, 2008.

[19] L. Tan, J. Su, D. Wu et al., “Kinetics and mechanism study of competitive inhibition of Jack-Bean urease by baicalin,” *The Scientific World Journal*, vol. 2013, Article ID 879501, 9 pages, 2013.

[20] Y.-C. Xie and F. Tang, “Protective effect of *Pogostemon cablin* on membrane fluidity of intestinal epithelia cell in ischemia/reperfusion rats after ischemia/reperfusion,” *Zhongguo Zhong Xi Yi Jie He Za Zhi*, vol. 29, no. 7, pp. 639–641, 2009.

[21] J.-L. Yu, X.-S. Zhang, X. Xie, and R.-M. Wang, “Patchouli alcohol protects against lipopolysaccharide-induced acute lung injury in mice,” *The Journal of Surgical Research*, vol. 194, no. 2, pp. 537–543, 2015.

[22] H. W. Kim, S. J. Cho, B.-Y. Kim, S. I. Cho, and Y. K. Kim, “*Pogostemon cablin* as ROS scavenger in oxidant-induced cell death of human neuroglioma cells,” *Evidence-Based Complementary and Alternative Medicine*, vol. 7, no. 2, pp. 239–247, 2010.

[23] Y.-C. Tsai, H.-C. Hsu, W.-C. Yang, W.-J. Tsai, C.-C. Chen, and T. Watanabe, “α-Bulnesene, a PAF inhibitor isolated from the
essential oil of *Pogostemon cablin*, "Fitoterapia", vol. 78, no. 1, pp. 7–11, 2007.

[24] Y. Yang, K. Kinoshita, K. Koyama et al., “Anti-emetic principles of *Pogostemon cablin* (Blanco) Bentham,” *Phytochemistry*, vol. 6, no. 2, pp. 89–93, 1999.

[25] J. B. Jeong, J. Choi, Z. Lou, X. Jiang, and S.-H. Lee, “Patchouli alcohol, an essential oil of *Pogostemon cablin*, exhibits anti-tumorogenic activity in human colorectal cancer cells,” *International Immunopharmacology*, vol. 16, no. 2, pp. 184–190, 2013.

[26] J. Yu, Y. Qi, G. Luo, H.-Q. Duan, and J. Zhou, “Extraction and analysis of the essential oil in *Pogostemon cablin* by enzymatic hydrolysis and inhibitory activity against Hela cell proliferation,” *Zhong Yao Cai*, vol. 35, no. 5, pp. 796–799, 2012.

[27] D. J. Giard, S. A. Aaronson, G. J. Todoroe et al., “In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors,” *Journal of the National Cancer Institute*, vol. 51, no. 5, pp. 1417–1423, 1973.

[28] A. Spira, B. Halmos, and C. A. Powell, “Update in lung cancer,” *American Journal of Respiratory and Critical Care Medicine*, vol. 192, no. 3, pp. 283–294, 2015.

[29] G. P. Kalemkerian, "Advances in pharmacotherapy of small cell lung cancer," *Expert Opinion on Pharmacotherapy*, vol. 15, no. 16, pp. 2385–2396, 2014.

[30] R. Sundar, R. Soong, B.-C. Cho, J. R. Brahmer, and R. A. Soo, “Immunotherapy in the treatment of non-small cell lung cancer,” *Lung Cancer*, vol. 85, no. 2, pp. 101–109, 2014.

[31] H. Shi, B. Tan, G. Ji et al., “Zedoary oil (Ezhu You) inhibits proliferation of AGS cells,” *Chinese Medicine*, vol. 8, no. 1, article 13, 2013.

[32] P. Li, D. Nijhawan, I. Budihardjo et al., “Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” *Cell*, vol. 91, no. 4, pp. 479–489, 1997.

[33] E. Ondroušková and B. Vojtěšek, “Programmed cell death in cancer cells,” *Klinická Onkologie*, vol. 27, supplement 1, pp. S7–S14, 2014.

[34] S. Thomas, B. A. Quinn, S. K. Das et al., “Targeting the Bcl-2 family for cancer therapy,” *Expert Opinion on Therapeutic Targets*, vol. 17, no. 1, pp. 61–75, 2013.

[35] A. Shamas-Din, J. Kale, B. Leber, and D. W. Andrews, “Mechanisms of action of Bcl-2 family proteins,” *Cold Spring Harbor Perspectives in Biology*, vol. 5, no. 4, Article ID a008714, 2013.

[36] M. Degli Esposti and C. Dive, “Mitochondrial membrane permeabilisation by Bax/Bak,” *Biochemical and Biophysical Research Communications*, vol. 304, no. 3, pp. 455–461, 2003.

[37] J. Estaquier, F. Vallette, J.-L. Vayssiere, and B. Mignotte, “The mitochondrial pathways of apoptosis,” in *Advances in Mitochondrial Medicine*, R. Scatena, P. Bottoni, and B. Giardina, Eds., vol. 942 of *Advances in Experimental Medicine and Biology*, pp. 157–183, 2012.

[38] J. D. Ly, D. R. Grubb, and A. Lawen, “The mitochondrial membrane potential (ΔΨm) in apoptosis; an update,” *Aptoptosis*, vol. 8, no. 2, pp. 115–128, 2003.

[39] M. P. Cunningham, S. Essapen, H. Thomas et al., “Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer,” *International Journal of Oncology*, vol. 27, no. 2, pp. 317–325, 2005.

[40] M. Shimizu, A. Deguchi, J. T. E. Lim, H. Moriwaki, L. Kopelovich, and I. B. Weinstein, “(−)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells,” *Clinical Cancer Research*, vol. 11, no. 7, pp. 2735–2746, 2005.

[41] P. K. Kandala, S. E. Wright, and S. K. Srivastava, “Blocking epidermal growth factor receptor activation by 3,3′-diin-dolylmethane suppresses ovarian tumor growth in vitro and in vivo,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 341, no. 1, pp. 24–32, 2012.

[42] M. R. Maiello, A. D’Alessio, S. Bevilacqua, M. Gallo, N. Normanno, and A. De Luca, “EGFR and MEK blockade in triple negative breast cancer cells,” *Journal of Cellular Biochemistry*, vol. 116, no. 12, pp. 2778–2785, 2015.

[43] S. M. Gadgeel, S. Ali, P. A. Philip, F. Ahmed, A. Wozniak, and F. H. Sarkar, “Response to dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor,” *Cancer*, vol. 110, no. 12, pp. 2775–2784, 2007.

[44] L. Li, Y. Gao, L. Zhang, J. Zeng, D. He, and Y. Sun, “Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma,” *Cancer Letters*, vol. 272, no. 1, pp. 61–69, 2008.